Asthma is one of the most common chronic diseases worldwide and can often be controlled by existing treatments, but in the 5-10% of patients with severe asthma, control is frequently more challenging. The aim of this paper is to evaluate the adherence to preventer inhaler therapy in severe asthmatic patients receiving omalizumab, a recombinant humanized monoclonal anti-IgE antibody indicated for moderate-to-severe asthma.
This study included 29 patients who were receiving omalizumab treatment as maintenance therapy. All patients completed the six questionTurkish Modified Morisky Scale. In addition, patients were classifiedby adherence to their prescribed preventer therapy, based on pharmaceutical and medical device institution records from the preceding one year.
Of the 29 enrolled patients, 24.1% had NSAID-exacerbated respiratory disease; 75.9% were female, and median age was 47.2±12.99 years.Severe asthma patients demonstrated high levels of motivation (98.8%,n=28) and knowledge (86.2%, n=22) about asthma treatment. Nevertheless, the rate of non-adherence to preventer inhaler therapy was only 34.5% (n=10). There were no significant differences amongst the characteristics of the patients that might affect the adherence to inhaler therapy.
In patients with severe asthma, suboptimal adherence to preventer inhaler therapy is common before and after omalizumab treatment. Although patients have high levels of motivation and knowledge about asthma treatment, adherence to inhaler preventer therapy declined after omalizumab therapy. Given these findings, it is important to decide whether preventer inhaler therapy should be continued as monotherapy or be discontinued inpatients exhibiting impaired adherence to biological agents, such as omalizumab.

This article is protected by copyright. All rights reserved.